The Arcadia Biosciences, Inc. (NASDAQ:RKDA) is going up by 12.48% in today’s trading session, a rise equivalent to 0.88% of the stock’s price from yesterday’s market close. A news came out on 08/12/19 stating that Thinking about buying stock in Aurora Cannabis, Arcadia Biosciences, Roku, Tilray, or Yangtze River Port and Logistics? by WSJ. The lowest point that the shares touched during the trading session was $5.22, while the peak of the day was recorded at a share price of $7.30. RKDA finished the previous session at $7.05 according to the data provided by Barchart, while the trading volume was observed to be $9,343,727.
In the 100 days of trading, RKDA managed to top a 4.72% Moving average. Additionally, Arcadia Biosciences, Inc. shares have achieved a 52-week range between 1.82 and 10.40 alongside 100 days raw stochastic set at 84.05%.
The number of shares outstanding, according to the fundamentals of the company, is set at 2.79M, equal to the value of $19.67M in market capitalization. Financial analysts indicate that RKDA shares should be still ranked as a “Buy”. In the last 30 days, Arcadia Biosciences, Inc. shares went down by -12.78%, adding 9.15 to growth in value, on top of a +338.52% boost since 07/15/19.
Arcadia Biosciences, Inc. (NASDAQ:RKDA) Analyst’s Estimates
Arcadia Biosciences, Inc. (RKDA) could record at least -$0.91 per share in quarterly earnings in the upcoming report on 08/14/2019, a number that would actually represent an increase of 45.50% YOY.
According to the average analyst rating, Arcadia Biosciences, Inc. would be rated as 1.50. Out of 2 different analysts monitoring RKDA stock, 1 analysts rate the stock as a BUY, 0 suggest to give the rating of HOLD, 1 indicate that RKDA is an OUTPERFORM, 0 rated the stock as a SELL, and 0 analyst believes that the stock should be rated as UNDERPERFORM.
On May-12-17, the stock earned a Downgrade rating due to a new analyst call from Piper Jaffray, while analysts from Piper Jaffray believe that the stock is set at Overweight, as concluded on Jun-09-15. Credit Suisse, is still rather wary about the stock, deciding to keep the rating at Outperform as confirmed through a call on Jun-09-15.
RKDA Key Ratios To Watch:
Taking in account the profitability of the Company, gross profit margin of +54.85% has been attained, while the operating margin has been recorded at -1152.32%. The firm is also showcasing profitability through returns on assets in the company’s ownership, with ROA set at -66.41%. Beta value of the stock is recorded at -1.98. Additionally, Arcadia Biosciences, Inc. is recording price volatility of 40.15% for the period of the last seven days and 16.90% in the last 30 days.
Arcadia Biosciences, Inc. (NASDAQ:RKDA) Technical Outlook
For the period of the last 50 days, Arcadia Biosciences, Inc. had its Raw Stochastic average set at 84.05% for the latest technical analysis. In comparison to the period of the last 20 days, the present Raw Stochastic average for the last 50 days poses as improvement, set at 84.05%. Stochastic %K for Arcadia Biosciences, Inc., with the last 20 days included, was set at 85.28%, having Stochastic %D topping 86.12%. Based on the previous performance of the company for the mentioned period, there are more than several recorded moving trends. When it comes to the period of the last 12 months, accounting the time for year-to-date, price performance appears to be encouraging for Arcadia Biosciences, Inc. stocks with recording 21.76% in metrics.
Arcadia Biosciences, Inc. Insider Watch:
As far as the position of shares issued by Arcadia Biosciences, Inc. (NASDAQ:RKDA) for the period concluded at the market close of 08/14/19, 9 institutional investors increased their positions in RKDA shares by 319,530, 4 decreased positions by 43,338 and 4 institutional investors decided to hold positions at 106,097. These numbers put the complete list of institutional holdings set at 468,965 shares, in accordance with filings submitted to the Securities and Exchange Commission. The stock had another 5 institutional investments with 183,652 new shares in addition to having 4 institutional investors selling their positions in 43,338 shares.